- Home
- ZLAB vs GBDC Comparison
ZLAB vs GBDC Comparison
Compare ZLAB & GBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZLAB
- GBDC
- Stock Information
- Founded
- ZLAB 2013
- GBDC 2009
- Country
- ZLAB China
- GBDC United States
- Employees
- ZLAB N/A
- GBDC N/A
- Industry
- ZLAB Biotechnology: Pharmaceutical Preparations
- GBDC Finance: Consumer Services
- Sector
- ZLAB Health Care
- GBDC Finance
- Exchange
- ZLAB Nasdaq
- GBDC Nasdaq
- Market Cap
- ZLAB 3.6B
- GBDC 4.0B
- IPO Year
- ZLAB 2017
- GBDC 2010
- Fundamental
- Price
- ZLAB $38.53
- GBDC $15.10
- Analyst Decision
- ZLAB Buy
- GBDC Buy
- Analyst Count
- ZLAB 5
- GBDC 4
- Target Price
- ZLAB $54.28
- GBDC $15.50
- AVG Volume (30 Days)
- ZLAB 769.8K
- GBDC 1.1M
- Earning Date
- ZLAB 08-07-2025
- GBDC 08-04-2025
- Dividend Yield
- ZLAB N/A
- GBDC 11.62%
- EPS Growth
- ZLAB N/A
- GBDC N/A
- EPS
- ZLAB N/A
- GBDC 1.18
- Revenue
- ZLAB $418,326,000.00
- GBDC $830,269,000.00
- Revenue This Year
- ZLAB $44.07
- GBDC $21.93
- Revenue Next Year
- ZLAB $49.13
- GBDC N/A
- P/E Ratio
- ZLAB N/A
- GBDC $12.72
- Revenue Growth
- ZLAB 43.72
- GBDC 28.08
- 52 Week Low
- ZLAB $16.01
- GBDC $12.68
- 52 Week High
- ZLAB $44.34
- GBDC $16.01
- Technical
- Relative Strength Index (RSI)
- ZLAB 57.47
- GBDC 49.15
- Support Level
- ZLAB $36.51
- GBDC $14.88
- Resistance Level
- ZLAB $41.20
- GBDC $15.55
- Average True Range (ATR)
- ZLAB 1.17
- GBDC 0.22
- MACD
- ZLAB 0.45
- GBDC -0.03
- Stochastic Oscillator
- ZLAB 71.89
- GBDC 22.67
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
About GBDC Golub Capital BDC Inc.
Golub Capital BDC Inc is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and capital appreciation by investing in senior secured and one-stop loans in United States middle-market companies. It also invests in the second lien and subordinated loans, warrants, and minority equity securities in United States middle-market companies. The company generally invests in securities that have been rated below investment grade by independent rating agencies or that would be rated below investment grade if rated. Maximum investment is done in USA and Canadian Companies, with maximum profit earned from those countries.